Tradegate
23.09.25 | 17:24
22,020 Euro
+2,71 % +0,580
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,960 | 22,500 | 21:12 | |
| 22,140 | 22,560 | 21:12 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:06 | Teva and Medincell's Risperidone LAI Approved in Canada as LONGAVO | 194 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI... ► Artikel lesen | |
| Mo | Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed | 188 | AFX News | PETAH TIKVA (dpa-AFX) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first... ► Artikel lesen | |
| Mo | Medincell: New Data Show that UZEDY Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna | 184 | Business Wire | UZEDY was associated with a 2.89-day shorter length of hospital stay compared with Invega Sustenna (paliperidone palmitate) This translates to estimated direct cost savings of $3200 per hospitalization... ► Artikel lesen | |
| MEDINCELL Aktie jetzt für 0€ handeln | |||||
| Mo | Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile - No PDSS Observed | 207 | Business Wire | There were no suspected or confirmed PDSS (Post-injection Delirium/Sedation Syndrome)1 events observed with Medincell's Olanzapine LAI through week 56 in the pivotal Phase 3 SOLARIS trial2 The... ► Artikel lesen | |
| Mi | Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation | 349 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 21, 2025,... ► Artikel lesen | |
| 12.09. | Medincell Appoints Three New Members to Board of Directors | 2 | Contract Pharma | ||
| 12.09. | Medincell appoints three biotech veterans to board of directors | 1 | Investing.com | ||
| 12.09. | Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors | 380 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch,... ► Artikel lesen | |
| 10.09. | Medincell: UZEDY Approved in South Korea Following Successful US Launch | 292 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Handok announced today that UZEDY, Long-Acting Injectable Risperidone for Schizophrenia, has received regulatory approval from the South Korean... ► Artikel lesen | |
| 05.09. | Medincell to Present at the H.C. Wainwright 27th Global Investment Conference and Participate in the Morgan Stanley 23rd Global Healthcare Conference | 379 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, Chief Executive Officer, will participate along with Dr Grace Kim, Chief Strategy Officer, U.S. Finance, in the following September... ► Artikel lesen | |
| 03.09. | Medincell: Reminder of the Participation Terms in the Combined General Meeting | 339 | Business Wire | Regulatory News:
The Annual General Meeting and Extraordinary General Meeting will be held at Medincell's (Paris:MEDCL) headquarters (3 rue des Frères Lumière, 34830 Jacou, France) on Thursday... ► Artikel lesen | |
| 04.08. | Medincell: Notice of the 2025 Annual General Meeting Published | 470 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) combined annual general meeting (ordinary and extraordinary) will be held on September 11, 2025, at 6pm at the Company's headquarters. The notice... ► Artikel lesen | |
| 30.07. | Medincell: UZEDY Accelerates: 2025 Revenue Outlook Raised to $190-$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025 | 511 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information:
About UZEDY
1-Month and 2-Month subcutaneous risperidone for schizophrenia
Commercialized... ► Artikel lesen | |
| 30.07. | Medincell Announces the Availability of its 2024-25 Universal Registration Document including the Annual Financial and CSR Reports | 473 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
The 2024-25 Universal Registration Document (URD) filed with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference... ► Artikel lesen | |
| 29.07. | Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch | 583 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful... ► Artikel lesen | |
| 24.07. | Medincell: Half-Year Liquidity Contract Statement | 424 | Business Wire | Regulatory News:
Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2025:... ► Artikel lesen | |
| 17.06. | Medincell Publishes its Consolidated Annual Financial Results | 526 | Business Wire | (April 1st, 2024 March 31st, 2025) Consolidated financial statements for the year 2024-25 (IFRS standards) Revenues: €25.4 million, multiplied by 2.8x compared to previous year
? Other... ► Artikel lesen | |
| 10.06. | Medincell to Present 2024-2025 Annual Results on June 17, 2025 | 572 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will... ► Artikel lesen | |
| 28.05. | Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025 | 590 | Business Wire | Regulatory News:
Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the... ► Artikel lesen | |
| 28.05. | Truist Securities Initiates Medincell's Coverage with a "Buy" Recommendation | 616 | Business Wire | Truist Securities, a leading U.S. investment bank with deep expertise in healthcare, has initiated coverage of Medincell The Truist Securities equity research team has issued a "Buy" rating on... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,85 | -0,90 % | Laufende Fusionskontrollverfahren: BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., Tübingen | Datum der Anmeldung:18.09.2025Aktenzeichen:B3-86/25Unternehmen:BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., TübingenProduktmärkte:biotechnologische... ► Artikel lesen | |
| EVOTEC | 6,208 | -1,93 % | EQS-DD: Evotec SE: Paul Hitchin, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
16.09.2025 / 12:06... ► Artikel lesen | |
| MEDIGENE | 0,066 | +0,91 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| QIAGEN | 38,865 | -0,30 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
| CUREVAC | 4,528 | -0,18 % | CureVac: BRUTALER Kurseinbruch - der wahre Grund jetzt enthüllt!!! | ||
| MODERNA | 21,840 | -2,95 % | Moderna, Inc.: Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans | Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groupsBoth of Moderna's COVID-19 vaccines for the... ► Artikel lesen | |
| PAION | 0,015 | -39,20 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| VALNEVA | 4,252 | -1,02 % | Valneva-Aktie springt an: Chikungunya-Alarm in Italien! | Die Ausbreitung des Chikungunya-Virus, welches durch die Tigermücke übertragen wird, bereitet zusehends auch in Europa Probleme. Allen voran in Italien wachsen die Sorgenfalten. Die Aktie des europäischen... ► Artikel lesen | |
| AMGEN | 242,00 | -0,21 % | EMA Backs Amgen Drug For Rare Autoimmune Disorder | ||
| NOVAVAX | 7,406 | -1,42 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| STRYKER | 315,90 | -1,47 % | Siemens Healthineers kooperiert für Robotersystem mit Stryker | DJ Siemens Healthineers kooperiert für Robotersystem mit Stryker
DOW JONES--Siemens Healthineers will ein Robotersystem für die Behandlung von Schlaganfällen und Aneurysmen gemeinsam mit dem US-Medizintechnologieunternehmen... ► Artikel lesen | |
| BIOGEN | 118,05 | -0,96 % | Biogen-Medikament gegen Wochenbettdepression in der EU zugelassen | BRÜSSEL (dpa-AFX) - Frauen mit Wochenbettdepression haben in der EU künftig Zugang zu einem neuen Medikament. Die Europäische Kommission hat Zuranolon vom US-Konzern Biogen die EU-weite Marktzulassung... ► Artikel lesen | |
| BIOFRONTERA | 2,780 | -1,07 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG: Neue Prognose | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG: Neue Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Biofrontera AG: Biofrontera AG: Neue Prognose
Leverkusen (pta000/01.08.2025/12:00... ► Artikel lesen | |
| HEIDELBERG PHARMA | 3,470 | -1,14 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma gibt die Präsentation neuer klinischer Daten des führenden ATAC-Kandidaten HDP-101 auf der International Myeloma Society-Jahrestagung 2025 bekannt | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Konferenz
Heidelberg Pharma gibt die Präsentation neuer klinischer Daten des führenden ATAC-Kandidaten HDP-101 auf der International... ► Artikel lesen | |
| ILLUMINA | 84,68 | -1,55 % | Illumina, Inc.: Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine | Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicinesMembers leverage AI-powered dataset to accelerate... ► Artikel lesen |
MEDINCELL SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,580 (+2,71 %) liegt der Kurs bei 22,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDINCELL SA finden Sie auf Wallstreet Online.